Fortress Biotech (FBIO)


(“Fortress” or “the Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products.  Fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also … Continue reading

Sunesis Pharmaceuticals (SNSS)


Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of … Continue reading

ProQR Therapeutics N.V. (PRQR)

ProQR Therapeutics is a Leiden, NL based biotech company focused on development of drugs to treat severe genetic disorders. Based on a novel proprietary technology we discover and develop drugs to change the lives of patients around the world. Founded … Continue reading

Corbus Pharmaceuticals Holdings, Inc. (CRBP)


Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate Resunab™ is a novel oral drug that … Continue reading

Matinas BioPharma (NASDAQ: MTNB)


Matinas BioPharma is a development stage biopharmaceutical company, founded in 2011, with a focus on identifying and developing novel pharmaceutical products for the treatment of abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular and metabolic … Continue reading

Tenax Therapeutics, Inc. (NASDAQ: TENX)


Tenax Therapeutics, Inc. (formerly Oxygen Biotherapeutics) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The company owns the North American rights to develop and commercialize levosimendan, and the United … Continue reading

DelMar Pharmaceuticals (OTC: DMPI)


DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company’s lead asset, VAL-083, is currently undergoing clinical trials in the United … Continue reading

ContraFect Corporation (NASDAQ: CFRX)


ContraFect Corporation is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the … Continue reading

Medgenics, Inc. (MDGN)


Medgenics is a medical technology and therapeutics company focused on providing sustained protein therapies. The Company has developed proprietary technology called the Biopump Platform, which uses the patient’s own tissue to continuously produce and deliver the patient’s own protein therapy. … Continue reading

Medicinova (MNOV)


MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova’s current strategy is to focus on MN-166 … Continue reading

Fibrocell Science (FCSC)


Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, … Continue reading

TONIX Pharmaceuticals (TNXP)


TONIX is developing innovative prescription medications for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX’s core technology improves … Continue reading

TG Therapeutics (TGTX)


TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently we are developing ublituximab (TGTX-1101), a novel, third … Continue reading

Cipher Pharmaceuticals (CPHR)


Cipher Pharmaceuticals is a drug development company focused on commercializing novel formulations of currently marketed molecules that have been improved through advanced drug delivery technologies. Cipher’s lead compound, CIP-FENOFIBRATE, is marketed in the United States by Kowa Pharmaceuticals America under … Continue reading

22nd Century Group, Inc. (XXII)


Founded in 1998, 22nd Century Limited, LLC (22nd Century) is a plant biotechnology company whose proprietary technology allows for the level of nicotine (and other nicotinic alkaloids) in the tobacco plant to be decreased or increased through genetic engineering and … Continue reading

Ventrus Biosciences (VTUS)


Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence. There are approximately 12.5 million Americans suffering from hemorrhoids, 7 million from fecal incontinence … Continue reading

Threshold Pharmaceuticals, Inc. (THLD)


Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline … Continue reading

Dynavax Technologies Corporation (DVAX)


Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases.  Our clinical-stage product candidates include: Phase 3 HEPLISAV ™ Hepatitis B Vaccine Phase 1 Universal Flu Vaccine Phase 1 … Continue reading

Keryx Biopharmaceuticals (KERX)


Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the … Continue reading



ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on the development of three clinical programs for multiple indications. Palifosfamide (ZIO-201) is a novel molecule … Continue reading